Ownership and insider activity for Arcutis Biotherapeutics, Inc. (ARQT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds.
Price
| Price | $26.14 |
| Market Cap | $3.3B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-08 | Matsuda Masaru | S-Sale | 9,989 | $250K |
| 2026-08-27 | Curran Terrie | M-Exempt | 27,052 | $233K |
| 2026-08-27 | Curran Terrie | M-Exempt | 11,148 | $84K |
| 2026-08-27 | Curran Terrie | S-Sale | 27,052 | $677K |
| 2026-08-27 | Curran Terrie | M-Exempt | 27,052 | $233K |
| 2026-08-27 | Curran Terrie | M-Exempt | 11,148 | $84K |
| 2026-08-20 | Curran Terrie | M-Exempt | 1,072 | $8K |
| 2026-08-20 | Curran Terrie | S-Sale | 1,072 | $28K |
| 2026-08-20 | Curran Terrie | M-Exempt | 1,072 | $8K |
| 2026-08-19 | Burnett Patrick | S-Sale | 1,697 | $46K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.4M | $39.4M | $63.3M | $65.1M | $98.0M | $53.6M | $88.4M | $71.3M | $42.9M |
| Short-term Investments | 0 | $11.5M | $37.9M | $219.4M | $290.6M | $355.9M | $183.5M | $156.6M | $178.1M |
| Receivables | 0 | 0 | 0 | $510000 | $362000 | $8.5M | $25.8M | $73.1M | $146.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 | $7.5M | $13.1M | $14.5M | $22.6M |
| Total Current Assets | $3.8M | $51.1M | $106.5M | $292.8M | $402.8M | $437.4M | $330.4M | $335.8M | $411.2M |
| Property, Plant & Equipment | 0 | 0 | $491000 | $5.4M | $5.3M | $4.6M | $3.9M | $3.0M | $5.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | $7.2M | $6.4M | $9.5M | $14.8M |
| Total Assets | $3.8M | $51.1M | $107.0M | $298.3M | $408.2M | $449.3M | $341.4M | $348.9M | $433.0M |
| Accounts Payable | $537000 | $1.8M | $1.4M | $7.1M | $7.4M | $8.8M | $12.0M | $14.2M | $12.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | $433000 | 0 | 0 | 0 | $1.0M |
| Total Current Liabilities | $692000 | $2.7M | $5.2M | $22.6M | $33.3M | $37.8M | $46.7M | $81.0M | $129.8M |
| Long-term Debt | $966000 | 0 | 0 | 0 | $72.3M | $197.8M | $201.8M | $107.2M | $5.3M |
| Total Liabilities | $8.8M | $75.1M | $5.5M | $27.6M | $110.5M | $239.7M | $252.7M | $191.3M | $243.5M |
| Retained Earnings | -$5.0M | -$24.3M | -$66.3M | -$201.9M | -$408.3M | -$719.8M | -$981.9M | -$1.12B | -$1.14B |
| Total Equity | -$5.0M | -$24.0M | $101.5M | $270.6M | $297.7M | $209.6M | $88.7M | $157.5M | $189.5M |
| Total Debt | $966000 | 0 | $307000 | $5.0M | $77.6M | $202.5M | $205.9M | $110.6M | $6.3M |
| Net Debt | -$2.5M | -$50.9M | -$101.0M | -$279.5M | -$311.0M | -$207.0M | -$65.9M | -$117.4M | -$214.7M |
| Working Capital | $3.1M | $48.4M | $101.2M | $270.2M | $369.4M | $399.6M | $283.8M | $254.8M | $281.4M |
Financial Health
| Debt / Equity | 0.52 |
| Current Ratio | 2.92 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 6.98 |
Profitability
| Return on Equity | -8.52% |
| Return on Invested Capital | -4.02% |
| Return on Assets | -3.73% |
| Gross Margin | 91.14% |
| Operating Margin | 7.38% |
| Net Margin | 6.15% |
Related companies: CELC · CGON · CNTA · FOLD · IRON · LEGN · TARS
Explore sector: Healthcare · Biotechnology
More sections of ARQT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks